Cancer genetics, inc (CGIX)
CashFlow / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent

-20,373

-20,880

-15,803

-20,184

-16,643

-12,373

-6,665

-19,887

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

1,602

1,799

2,032

1,503

810

311

338

356

Amortization

512

366

343

159

28

15

15

13

Provision for bad debts

2,514

5,278

723

413

215

0

-4

372

Stock-based compensation

921

1,895

2,016

2,834

3,835

735

-

-

Stock issued for consulting services

0

5

75

0

-

-

-

-

Change in fair value of warrant liability, acquisition note payable and other derivatives

-3,782

2,006

-

-

-

-

-

-

Equity-based consulting and compensation expenses

-

-

-

-

-

-

915

1,093

Stock-based research and development/general and administrative expenses

-

-

-

-

0

427

0

69

Change in fair value of acquisition note payable

-

-

-152

-269

-198

0

0

-

Change in fair value of warrant liability

-

-

-1,525

-35

-417

-4,633

-7,538

10,388

Extension of warrants

-

-

-

-

-

-

144

-

Amortization of discount of debt and debt issuance costs

517

1,299

12

8

311

1,195

1,427

575

Amortization of discount on debt

-

-

0

-

-

-

-

-

Loss on disposal of fixed assets and sale of India subsidiary

-204

0

-

-

-

-

-

-

Modification of 2017 Debt warrants

83

0

-

-

-

-

-

-

Accretion of discount on debt

-

-

-

-

0

585

2,212

480

Deferred rent

-

-

-

-

-

-

7

25

Income (Loss) from Equity Method Investments

-154

-22

-73

-707

-940

-12

0

-

Loss on extinguishment of debt

0

-78

0

-

-

-

-

-

Loss on debt and warrant restructuring

-

-

-

-

-

-

-1,862

-

Loss on conversion of debt to equity

-

-

-

-

0

6,850

0

-

Deferred initial public offering costs expensed

-

-

-

-

0

618

0

-

Changes in:
Accounts receivable

-1,041

3,583

5,850

1,662

1,657

717

156

355

Other current assets

-330

159

56

384

199

375

220

-551

Other non-current assets

-1

0

69

101

0

0

-

-

Accounts payable, accrued expenses and deferred revenue

3,766

-1,538

355

3,114

675

-731

85

1,243

Deferred rent payable and other

42

152

25

33

38

-6

-

-

Net cash used in operating activities

-12,552

-13,564

-17,851

-13,599

-12,338

-8,075

-7,577

-5,073

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets

649

1,284

490

1,008

1,374

257

162

268

Decrease in restricted cash

-

-

0

-6,000

6,000

50

50

-238

Patent costs

31

126

119

137

130

92

135

82

Purchase of cost method investment

0

200

0

-

-

-

-

-

Cash received in the sale of India subsidiary, net of cash transferred

1,764

0

-

-

312

0

-

-

Investment in joint venture

-

-

-

-

1,000

1,000

0

-

Cash used in acquisition of vivoPharm, Pty Ltd., net of cash received

0

1,091

0

-

3,181

0

-

-

Cash used in acquisition of Response Genetics

-

-

-

7,495

0

0

-

-

Net cash provided by investing activities

1,084

-2,701

-609

-2,640

-11,373

-1,399

-347

-113

CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on obligations under finance leases

337

230

126

83

44

17

36

42

Payment of equity issuance costs

-

-

-

117

0

0

-

-

Proceeds from public offerings of equity, net of offering costs

-

-

-

10,353

0

61,517

0

-

Proceeds from warrant and option exercises

0

1,834

0

1

178

192

635

49

Proceeds from option exercises

-

-

0

23

79

1

0

-

Proceeds from borrowings on notes payable

-

-

-

-

-

-

7,120

3,000

Payments on line of credit

-

-

-

-

-

-

0

-200

Proceeds from borrowings on Silicon Valley Bank line of credit

12,055

4,137

0

-

-

-

0

3,200

Repayment of borrowings on Silicon Valley Bank line of credit

13,571

0

-

-

-

-

-

-

Proceeds from Convertible Note

2,500

0

-

-

-

-

-

-

Advance from NovellusDx, Ltd.

1,500

0

-

-

-

-

-

-

Proceeds from Partners for Growth IV, L.P. term note

0

6,000

0

-

-

-

-

-

Payment of debt issuance costs

0

287

0

33

0

0

1,373

182

Principal payments on Silicon Valley Bank term note

0

4,667

1,333

0

408

3,580

17

-

Net cash provided by financing activities

2,147

16,338

8,503

10,144

-195

58,114

6,328

5,824

Effect of foreign exchange rates on cash and cash equivalents and restricted cash

-59

16

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents and restricted cash

-9,380

89

-

-

-

-

-

-

Net (decrease) in cash and cash equivalents

-

-

-9,957

-6,095

-23,906

48,640

-1,597

638

Effect of foreign currency exchange rates on cash and cash equivalents

-

-

0

-

-

-

-

-

SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest

1,271

871

333

240

128

608

1,091

253

SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangement

150

567

211

0

42

354

0

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

0

-

Reclassification of derivative warrants

-

-

-

-

0

7,170

0

-

Derivative warrants issued with debt

-

-

-

-

125

420

0

-

Fixed assets acquired through capital lease arrangement

-

-

-

-

-

-

0

49

Warrants issued with debt

-

-

-

-

-

-

6,122

1,970

Warrants issued for debt guarantee fee

-

-

-

-

-

-

1,583

831

Warrants issued for financing fees

-

-

-

-

0

47

1,003

-

Retirement of treasury stock

-

-

-

-

0

17

0

-

Conversion of notes payable and lines of credit to common stock

-

-

-

-

0

9,634

0

-

Business Combination, Consideration Transferred, Equity Interests Issued and Issuable

0

8,084

0

-

1,516

0

0

-

Warrants and Rights, Reclassified

423

0

-

-

-

-

-

-

Disposal of Business:
Beneficial conversion feature

328

0

-

-

-

-

-

-

Loss on sale of India subsidiary

-78

0

-

-

-

-

-

-

Cash received in the sale of India subsidiary, net of cash transferred

1,764

0

-

-

-

-

-

-

Warrant liability reclassified to equity

-

-

-

-

-

-

-

6,415

Offering costs discounted

-

-

-

-

0

733

0

-

Net tangible assets acquired via acquisition

-

-

-

2,843

1,255

0

-

-

Accrued IPO costs

-

-

-

-

-

-

1,732

1,428

Accrued expenses recorded as financing fees

-

-

-

-

-

-

251

-

Accrued expenses reclassified as derivative warrant liability

-

-

-

-

0

221

148

-

Derivative warrant settled with accrued expense

-

-

-

-

-

-

182

-

2017 Offerings
Proceeds from offerings of equity, net of certain offering costs

0

6,586

-

-

-

-

-

-

Derivative warrants issued with debt

0

2,199

-

-

-

-

-

-

Common Stock Purchase Agreement
Proceeds from offerings of equity, net of certain offering costs

0

2,965

-

-

-

-

-

-

2017 Debt
Derivative warrants issued with debt

0

1,004

-

-

-

-

-

-

NDX
Beneficial conversion feature

1,173

0

-

-

-

-

-

-